中国妇幼健康研究
中國婦幼健康研究
중국부유건강연구
Chinese Journal of Woman and Child Health Research
2015年
4期
740-743
,共4页
部分性癫痫%奥卡西平%丙戊酸钠%疗效%认知
部分性癲癇%奧卡西平%丙戊痠鈉%療效%認知
부분성전간%오잡서평%병무산납%료효%인지
partial epilepsy%oxcarbazepine ( OXC)%valproic acid ( VPA)%therapeutic efficacy%cognition
目的 探讨奥卡西平( OXC)单药治疗新诊断的儿童部分性癫痫的临床疗效、安全性和对认知功能的影响,为儿童癫痫的治疗提供临床依据. 方法 92名部分性癫痫儿童,按就诊顺序分为OXC治疗组(46例)和丙戊酸钠(VPA)治疗组(46例),采用前瞻性对照研究的方法随访观察1 年,评价各治疗组治疗前后及各组间患儿的临床疗效、认知功能及不良反应.结果 临床疗效:两组患者随访3月癫痫发作控制率比较差异无统计学意义(χ2 =0.099,P>0.05);随访12月癫痫发作控制率比较差异均无统计学意义(χ2 =0.005,P>0.05). 认知功能:4.5~6岁OXC组患者言语测试、词汇较治疗前评分增高,差异均有统计学意义(t值分别为-3.050、-3.847,均P<0.05),6~14岁OXC组患者言语测试、词汇及数字广度分较治疗前测验评分增高,差异具有统计学意义( t值分别为-8.375、-6.129、-7.023,均P<0.05). 两组副作用均比较轻微. 结论 奥卡西平单药治疗新诊断儿童部分性癫痫疗效与丙戊酸钠相近,不良反应轻微,且对认知具有一定的改善作用.
目的 探討奧卡西平( OXC)單藥治療新診斷的兒童部分性癲癇的臨床療效、安全性和對認知功能的影響,為兒童癲癇的治療提供臨床依據. 方法 92名部分性癲癇兒童,按就診順序分為OXC治療組(46例)和丙戊痠鈉(VPA)治療組(46例),採用前瞻性對照研究的方法隨訪觀察1 年,評價各治療組治療前後及各組間患兒的臨床療效、認知功能及不良反應.結果 臨床療效:兩組患者隨訪3月癲癇髮作控製率比較差異無統計學意義(χ2 =0.099,P>0.05);隨訪12月癲癇髮作控製率比較差異均無統計學意義(χ2 =0.005,P>0.05). 認知功能:4.5~6歲OXC組患者言語測試、詞彙較治療前評分增高,差異均有統計學意義(t值分彆為-3.050、-3.847,均P<0.05),6~14歲OXC組患者言語測試、詞彙及數字廣度分較治療前測驗評分增高,差異具有統計學意義( t值分彆為-8.375、-6.129、-7.023,均P<0.05). 兩組副作用均比較輕微. 結論 奧卡西平單藥治療新診斷兒童部分性癲癇療效與丙戊痠鈉相近,不良反應輕微,且對認知具有一定的改善作用.
목적 탐토오잡서평( OXC)단약치료신진단적인동부분성전간적림상료효、안전성화대인지공능적영향,위인동전간적치료제공림상의거. 방법 92명부분성전간인동,안취진순서분위OXC치료조(46례)화병무산납(VPA)치료조(46례),채용전첨성대조연구적방법수방관찰1 년,평개각치료조치료전후급각조간환인적림상료효、인지공능급불량반응.결과 림상료효:량조환자수방3월전간발작공제솔비교차이무통계학의의(χ2 =0.099,P>0.05);수방12월전간발작공제솔비교차이균무통계학의의(χ2 =0.005,P>0.05). 인지공능:4.5~6세OXC조환자언어측시、사회교치료전평분증고,차이균유통계학의의(t치분별위-3.050、-3.847,균P<0.05),6~14세OXC조환자언어측시、사회급수자엄도분교치료전측험평분증고,차이구유통계학의의( t치분별위-8.375、-6.129、-7.023,균P<0.05). 량조부작용균비교경미. 결론 오잡서평단약치료신진단인동부분성전간료효여병무산납상근,불량반응경미,차대인지구유일정적개선작용.
Objective To investigate the clinical efficacy and security of oxcarbazepine ( OXC ) mono-therapy for treatment of newly diagnosed childhood partial epilepsy and the influence on cognitive function, so as to provide clinical evidence for the treatment of childhood epilepsy.Methods Ninety-two children with partial epilepsy were divided into OXC treatment group (46 cases) and valproic acid (VPA) treatment group (46 cases) according to treatment order.Prospective controlled study methods were used to follow up for one year, and the clinical efficacy, cognitive function and adverse reactions before and after treatment between two groups were evaluated. Results Two groups were not significantly different in seizure control rate during 3-month follow up and 12-month follow up (χ2 value was 0.099 and 0.005, respectively, both P>0.05).The scores of VIQ and vocabulary of children aged 4.5-6 years old in OXC group were obviously higher than those before treatment (t value was -3.050 and -3.847, respectively, both P <0.05), and those of VIQ, vocabulary and digital span of children aged 6-14 years old were significantly higher than those before treatment ( t value was -8.375,-6.129 and -7.023, respectively, all P<0.05).The adverse reactions of two groups were both relatively mild.Conclusion OXC mono-therapy for treatment of newly diagnosed partial childhood epilepsy has obtained similar efficacy with VPA.The adverse reactions are mild and cognition can be improved to some extend.
